Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Johnson and Johnson
Mallinckrodt
Medtronic
McKinsey

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,955,597

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,955,597
Title:Anti-IL-6 antibodies, compositions, methods and uses
Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Inventor(s): Giles-Komar; Jill (Downingtown, PA), Knight; David (Berwyn, PA), Peritt; David (Bala Cynwyd, PA), Trikha; Mohit (Paoli, PA)
Assignee: Centocor, Inc. (Malvern, PA)
Application Number:12/507,962
Patent Claims:1. A method for inhibiting tumor growth in a cell, tissue, organ or animal, or inhibiting cancer cachexia in an animal, comprising contacting or administering to said cell, tissue, organ or animal a pharmaceutically effective amount of an IL-6 antibody or fragment thereof comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO:7, a light chain variable region having the amino acid sequence of SEQ ID NO:8, and a constant region derived from one or more human antibodies.

2. A method according to claim 1, wherein said tumor or cancer is at least one selected from leukemia, acute leukemia, acute lymphoblastic leukemia, B-cell, T-cell or FAB acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, myelodyplastic syndrome, a lymphoma, Hodgkin's disease, a malignant lymphoma, non-hodgkin's lymphoma, Burkitt's lymphoma, multiple myeloma, Kaposi's sarcoma, colorectal carcinoma, pancreatic carcinoma, renal cell carcinoma, prostatic cell carcinoma, nasopharyngeal carcinoma, malignant histiocytosis, paraneoplastic syndrome/hypercalcemia of malignancy, solid tumors, adenocarcinomas, sarcomas, and malignant melanoma.

3. A method according to claim 1 wherein said effective amount is 0.01-100 mg/kilogram of said cells, tissue, organ or animal.

4. A method according to claim 1, further comprising administering, prior, concurrently or after said contacting or administering, at least one composition comprising a therapeutically effective amount of at least one compound or protein selected from at least one of a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anethetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteriod, an anabolic steroid, a diabetes related agent, a mineral, a nutritional, a thyroid agent, a vitamin, a calcium related hormone, an antidiarrheal, an antitussive, an antiemetic, an antiulcer, a laxative, an anticoagulant, an erythropieitin, a filgrastim, a sargramostim, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, an estrogen receptor modulator, a mydriatic, a cycloplegic, an alkylating agent, an antimetabolite, a mitotic inhibitor, a radiopharmaceutical, an antidepressant, antimanic agent, an antipsychotic, an anxiolytic, a hypnotic, a sympathomimetic, a stimulant, donepezil, tacrine, an asthma medication, a beta agonist, an inhaled steroid, a leukotriene inhibitor, a methylxanthine, a cromolyn, an epinephrine or analog, dornase alpha, a cytokine, a cytokine antagonist.

5. A method for inhibiting tumor growth in a cell, tissue, organ or animal, or inhibiting cancer cachexia in an animal comprising contacting or administering to said cell, tissue, organ or animal a pharmaceutically effective amount of an isolated antibody or antibody fragment that binds to human IL-6, comprising the heavy chain and light chain complementarity determining regions (CDRs) having the amino acid sequences of SEQ ID NOS:1-6, and a constant region derived from one or more human antibodies.

Details for Patent 7,955,597

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial Centocor, Inc. (Malvern, PA) 2039-03-29 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 002 1991-02-20   Start Trial Centocor, Inc. (Malvern, PA) 2039-03-29 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 003 1991-02-20   Start Trial Centocor, Inc. (Malvern, PA) 2039-03-29 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 004 1991-02-20   Start Trial Centocor, Inc. (Malvern, PA) 2039-03-29 RX search
Berlex Labs LEUKINE sargramostim VIAL 103362 001 1991-03-05   Start Trial Centocor, Inc. (Malvern, PA) 2039-03-29 RX search
Berlex Labs LEUKINE sargramostim VIAL 103362 002 1991-03-05   Start Trial Centocor, Inc. (Malvern, PA) 2039-03-29 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,955,597

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
AstraZeneca
McKesson
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.